Prior Authorization Request

EOC: Long Acting Opioids



Serve You Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Fill out electronically, or print using blue or black ink. If you have questions or need additional forms, visit <u>ServeYouRx.com</u> or call 800-759-3203.

Fax completed form to: 800-480-4840, Attn: Authorizations **Note:** Blank fields or illegible responses may delay the review process.

PATIENT INFORMATION							
Last Name:	First Name:		MI:				
Date of Birth: Member ID #:	Group #: City: State: ZIP:						
,	Secondary Phone #: Mobile □ Work □ Home						
☐ Mobile ☐ Work ☐ Home		□ Mobile □ Work	☐ Home				
PRESCRIBER INFORMATION							
Name:	S _l	pecialty:					
Address:	City:	State	e: ZIP:				
NPI: State License ID:							
Office Contact:	Fax:		Phone:				
REQUESTED MEDICATION							
Drug Name:	Strength:		Frequency:				
Directions:	_		- ' ' '				
	If this is a continuation of therapy, provide start date:						
☐ Pertinent medical history or information for this patient is attached that may support approval							
☐ Urgent review requested							
REQUIRED INFORMATION							
1 Please indicate if this request is for: 7 Has the patient tried and failed an adequate (minimum of							
☐ New Start ☐ Continuation of Therapy		4 week) trial of a short-acting opioid?					
2 Diagnosis for use:		☐ Yes ☐ No					
		8 For NON-NEUROPATHIC PAIN, is the medication being used for any of the following (see Question #9 below)? ☐ Yes ☐ No					
 4 Is the patient being treated for cancer related pain or pain associated with end of life? □ Yes (Please answer questions #5 and #6, if applicable; no other questions need to be answered.) □ No 5 For requests for Arymo ER, brand Kadian, Morphabond ER, Nucynta ER, Xtampza ER, or Zohydro ER, does the patient have a history of failure, contraindication, or intolerance to at least two of the following medications listed below: 							
					9 If yes to above: Please indicate if any of the following apply: □ For use as an as-needed PRN analgesic □ For pain that is mild or not expected to persist for an extended period of time		
		☐ For acute pain					
		10 For POSTOPERATIVE PAIN, do either of the following apply?					
		(see below)					
		If yes to above: Please indicate which of the following apply:□ Patient was already receiving chronic opioid therapy prior					
		6 If yes to above: Please indicate which medications	the	,	ceiving chronic opioid thera	py prior	
		patient has tried and failed: Generic hydromorphone ER		to surgery Postoperative pain is expected to be moderate to severe and persist for an extended period of time			
							Generic oxymorphone ER
		☐ Generic morphine sulfate ER☐ Embeda		For NEUROPATHIC PAIN, has the patient exhibited an adequate response to 8 weeks of treatment with gabapentin			
☐ Hysingla ER		titrated to a therapeutic dose?					
☐ Oxycontin		☐ Yes ☐ No					



Prior Authorization Request Form

EOC ID: Long Acting Opioids

Patient Last Name: ____ First Name: MI: 13 For NEUROPATHIC PAIN, has the patient exhibited an adequate response to at least 6-8 weeks of treatment with a tricyclic antidepressant titrated to a therapeutic dose? □ Yes □ No 14 For continuation of therapy, is documentation available that addresses **ALL** of the following? (please provide such documentation) ☐ Yes ☐ No 15 Please indicate which of the following apply, and provide documentation for each: ☐ Treatment goals and estimated duration of treatment ☐ Treatment plan including use of nonopioid analgesics and/or nonpharmacologic intervention ☐ Evidence that the patient has demonstrated meaningful improvement in pain and function using a validated instrument ☐ Evidence that the patient has been screened for substance abuse/opioid dependence using a validated instrument ☐ Evidence that the patient has been screened for comorbid mental health conditions ☐ An assessment of increased risk for respiratory depression, if applicable based on medical comorbidities and/or drug-drug interactions (e.g. benzodiazepines) ☐ Total daily morphine equivalent dose ☐ Rationale for not tapering or discontinuing the opioid **16** Additional comments: Prescriber Signature Date

Certain prescription benefit plans or situations may require additional information or clarification to evaluate a prior authorization request. For complete details about benefits, limitations, conditions and exclusions, please refer to the applicable plan.

The information contained in this document may be confidential, is intended only for the use of the recipient(s) named above, and may be legally privileged. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this document, or any of its contents, is strictly prohibited. If you have received this document in error, please notify the sender immediately and arrange for the return or destruction of the document. For questions, please contact the sender.